Collectively, these results suggested that patients with high expression of NNMT have a poor response to EGFR TKI, indicating that NNMT may be used to predict the efficacy of EGFR-TKI therapy in NSCLC patients. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.